uniQure N.V. QURE

NAS: QURE | ISIN: NL0010696654   20/05/2024
4,850 USD (-3,19%)
(-3,19%)   20/05/2024

7 mei 2024 · uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

28 februari 2024 · uniQure Announces 2023 Financial Results and Highlights Recent Company Progress · Persbericht

15 januari 2024 · Swissmedic autorise le traitement de thérapie génique HEMGENIX® (etranacogene dezaparvovec) de CSL pour les patients atteints d'hémophilie B · Persbericht

19 december 2023 · uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease · Persbericht

12 december 2023 · CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B · Persbericht

8 december 2023 · uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 november 2023 · uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease · Persbericht

7 november 2023 · uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress · Persbericht

27 oktober 2023 · CSL and uniQure Win 2023 Prix Galien USA Award · Persbericht

24 oktober 2023 · uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting · Persbericht

5 oktober 2023 · uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs · Persbericht

2 oktober 2023 · uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 september 2023 · uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy · Persbericht

2 september 2023 · Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 · Persbericht

1 augustus 2023 · uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress · Persbericht

26 juni 2023 · uniQure Announces Leadership Addition to Support Advancement of Clinical Programs · Persbericht

21 juni 2023 · uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease · Persbericht

20 juni 2023 · uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy · Persbericht

20 juni 2023 · CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B · Persbericht

16 juni 2023 · uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties